Function of phosphorylation of NF-κB p65 ser536 in prostate cancer oncogenesis

Oncotarget

Volumn 6, Issue 8, 2015, Pages 6281-6294

  Zhang, Li ^a,b   Shao, Longjiang ^b   Creighton, Chad J ^c   Zhang, Yiqun ^c   Xin, Li ^c   Ittmann, Michael ^b   Wang, Jianghua ^b  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

AKT; CCL2; NF B; Prostate cancer; TMPRSS2 ERG

Indexed keywords

MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN KINASE B; SERINE; TRANSCRIPTION FACTOR RELA; ERG PROTEIN, HUMAN; SERINE PROTEINASE; TMPRSS2 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR ERG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CELL MOTILITY; CELL TRANSFORMATION; CONTROLLED STUDY; EMBRYO; FUSION GENE; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PROSTATE CANCER; PROSTATE EPITHELIUM CELL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TMPRSS2 ERG GENE; TUMOR GROWTH; TUMOR PROMOTION; ANIMAL; GENE FUSION; GENETIC TRANSFECTION; GENETICS; HEK293 CELL LINE; METABOLISM; PHOSPHORYLATION; PROSTATE TUMOR; SCID MOUSE; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; CARCINOGENESIS; CELL LINE, TUMOR; GENE FUSION; HEK293 CELLS; HETEROGRAFTS; HUMANS; MALE; MICE; MICE, SCID; PHOSPHORYLATION; PROSTATIC NEOPLASMS; SERINE ENDOPEPTIDASES; SIGNAL TRANSDUCTION; TRANS-ACTIVATORS; TRANSCRIPTION FACTOR RELA; TRANSCRIPTIONAL REGULATOR ERG; TRANSFECTION;

EID: 84925594220     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3366     Document Type: Article

References (62)

1. Soller M J, Isaksson M, Elfving P, Soller W, Lundgren R, and Panagopoulos I. Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer, Genes Chromosomes Cancer 2006 45, 717-719.
2. Wang J, Cai Y, Ren C, and Ittmann M. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer, Cancer Res 2006 66, 8347-8351.
3. Yoshimoto M, Joshua A M, Cunha I W, Coudry R A, Fonseca F P, Ludkovski O, Zielenska M, Soares F A, and Squire J A. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome, Mod Pathol 2008 21, 1451-1460.
4. Cai C, Wang H, Xu Y, Chen S, and Balk S P. Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer, Cancer Res 2009 69, 6027-6032.
5. Tomlins S A, Rhodes D R, Perner S, Dhanasekaran S M, Mehra R, Sun X W, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie J E, Shah R B, Pienta K J, Rubin M A, and Chinnaiyan A M. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer, Science 2005 310, 644-648.
6. Demichelis F, Fall K, Perner S, Andren O, Schmidt F, Setlur S R, Hoshida Y, Mosquera J M, Pawitan Y, Lee C, Adami H O, Mucci L A, Kantoff P W, Andersson S O, Chinnaiyan A M, Johansson J E, and Rubin M A. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort, Oncogene 2007 26, 4596-9.
7. Clark J, Merson S, Jhavar S, Flohr P, Edwards S, Foster C S, Eeles R, Martin F L, Phillips D H, Crundwell M, Christmas T, Thompson A, Fisher C, Kovacs G, and Cooper C S. Diversity of TMPRSS2-ERG fusion transcripts in the human prostate, Oncogene 2006 26, 2667-73.
8. Cerveira N, Ribeiro F R, Peixoto A, Costa V, Henrique R, Jeronimo C, and Teixeira M R. TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions, Neoplasia 2006 8, 826-832.
9. Wang J, Cai Y, Yu W, Ren C, Spencer D M, and Ittmann M. Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts, Cancer research 2008 68, 8516-8524.
10. Shao L, Tekedereli I, Wang J, Yuca E, Tsang S, Sood A, Lopez-Berestein G, Ozpolat B, and Ittmann M. Highly specific targeting of the TMPRSS2/ERG fusion gene using liposomal nanovectors, Clin Cancer Res 2012 18, 6648-6657.
11. Wang J, Cai Y, Shao L J, Siddiqui J, Palanisamy N, Li R, Ren C, Ayala G, and Ittmann M M. Activation of NF-κB by TMPRSS2/ERG fusion isoforms through Toll-like receptor-4, Cancer research 2010 71, 1325-33.
12. Inoue J, Gohda J, Akiyama T, and Semba K. NF-kappaB activation in development and progression of cancer, Cancer Sci 2007 98, 268-274.
13. Jin R, Yi Y, Yull F E, Blackwell T S, Clark P E, Koyama T, Smith J A, Jr., and Matusik R J. NF-kappaB gene signature predicts prostate cancer progression, Cancer Res 2014 74, 2763-2772.
14. Shukla S, MacLennan G T, Fu P, Patel J, Marengo S R, Resnick M I, and Gupta S. Nuclear factor-kappaB/p65 (Rel A) is constitutively activated in human prostate adenocarcinoma and correlates with disease progression, Neoplasia 2004 6, 390-400.
15. Jain G, Cronauer M V, Schrader M, Moller P, and Marienfeld R B. NF-kappaB signaling in prostate cancer: a promising therapeutic target?, World J Urol 2012 30, 303-310.
16. Nguyen D P, Li J, Yadav S S, and Tewari A K. Recent insights into NF-kappaB signalling pathways and the link between inflammation and prostate cancer, BJU Int 2014 114, 168-176.
17. Domingo-Domenech J, Mellado B, Ferrer B, Truan D, Codony-Servat J, Sauleda S, Alcover J, Campo E, Gascon P, Rovira A, Ross J S, Fernandez P L, and Albanell J. Activation of nuclear factor-kappaB in human prostate carcinogenesis and association to biochemical relapse, Br J Cancer 2005 93, 1285-1294.
18. Jain G, Cronauer M V, Schrader M, Moller P, and Marienfeld R B. NF-kappaB signaling in prostate cancer: a promising therapeutic target?, World journal of urology 30, 303-310.
19. Jin R J, Lho Y, Connelly L, Wang Y, Yu X, Saint Jean L, Case T C, Ellwood-Yen K, Sawyers C L, Bhowmick N A, Blackwell T S, Yull F E, and Matusik R J. The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth, Cancer Res 2008 68, 6762-6769.
20. Kim J S, Roberts J M, Bingman W E, 3rd, Shao L, Wang J, Ittmann M M, and Weigel N L. The Prostate Cancer TMPRSS2:ERG Fusion Synergizes With the Vitamin D Receptor (VDR) to Induce CYP24A1 Expression-Limiting VDR Signaling, Endocrinology 2014 155, 3262-3273.
21. Vermeulen L, De Wilde G, Notebaert S, Vanden Berghe W, and Haegeman G. Regulation of the transcriptional activity of the nuclear factor-kappaB p65 subunit, Biochem Pharmacol 2002 64, 963-970.
22. Viatour P, Merville M P, Bours V, and Chariot A. Phosphorylation of NF-kappaB and IkappaB proteins: implications in cancer and inflammation, Trends Biochem Sci 2005 30, 43-52.
23. Shao L, Zhou Z, Cai Y, Castro P, Dakhov O, Shi P, Bai Y, Ji H, Shen W, and Wang J. Celastrol suppresses tumor cell growth through targeting an AR-ERG-NF-kappaB pathway in TMPRSS2/ERG fusion gene expressing prostate cancer, PLoS One 2013 8, e58391.
24. Sasaki C Y, Barberi T J, Ghosh P, and Longo D L. Phosphorylation of RelA/p65 on serine 536 defines an I{kappa}B{alpha}-independent NF-{kappa}B pathway, J Biol Chem 2005 280, 34538-34547.
25. Hu J, Nakano H, Sakurai H, and Colburn N H. Insufficient p65 phosphorylation at S536 specifically contributes to the lack of NF-kappaB activation and transformation in resistant JB6 cells, Carcinogenesis 2004 25, 1991-2003.
26. Hu J, Haseebuddin M, Young M, and Colburn N H. Suppression of p65 phosphorylation coincides with inhibition of IkappaBalpha polyubiquitination and degradation, Mol Carcinog 2005 44, 274-284.
27. Wang J, Cai Y, Shao L J, Siddiqui J, Palanisamy N, Li R, Ren C, Ayala G, and Ittmann M. Activation of NF-{kappa}B by TMPRSS2/ERG Fusion Isoforms through Toll-Like Receptor-4, Cancer research 71, 1325-1333.
28. Rao D S, Bradley S V, Kumar P D, Hyun T S, Saint-Dic D, Oravecz-Wilson K, Kleer C G, and Ross T S. Altered receptor trafficking in Huntingtin Interacting Protein 1-transformed cells, Cancer cell 2003 3, 471-482.
29. Pahl H L. Activators and target genes of Rel/NF-kappaB transcription factors, Oncogene 1999 18, 6853-6866.
30. Li X, Zhao Y, Tian B, Jamaluddin M, Mitra A, Yang J, Rowicka M, Brasier A R, and Kudlicki A. Modulation of gene expression regulated by the transcription factor NF-kappaB/RelA, J Biol Chem 2014 289, 11927-11944.
31. Loberg R D, Day L L, Harwood J, Ying C, St John L N, Giles R, Neeley C K, and Pienta K J. CCL2 is a potent regulator of prostate cancer cell migration and proliferation, Neoplasia 2006 8, 578-586.
32. Lu Y, Cai Z, Galson D L, Xiao G, Liu Y, George D E, Melhem M F, Yao Z, and Zhang J. Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion, Prostate 2006 66, 1311-1318.
33. Roca H, Varsos Z, and Pienta K J. CCL2 protects prostate cancer PC3 cells from autophagic death via phosphatidylinositol 3-kinase/AKT-dependent survivin up-regulation, J Biol Chem 2008 283, 25057-25073.
34. Lin T H, Liu H H, Tsai T H, Chen C C, Hsieh T F, Lee S S, Lee Y J, Chen W C, and Tang C H. CCL2 increases alphavbeta3 integrin expression and subsequently promotes prostate cancer migration, Biochim Biophys Acta 2013 1830, 4917-4927.
35. Roebuck K A, Carpenter L R, Lakshminarayanan V, Page S M, Moy J N, and Thomas L L. Stimulus-specific regulation of chemokine expression involves differential activation of the redox-responsive transcription factors AP-1 and NF-kappaB, J Leukoc Biol 1999 65, 291-298.
36. Wang J, Cai Y, Shao L J, Siddiqui J, Palanisamy N, Li R, Ren C, Ayala G, and Ittmann M. Activation of NF-{kappa}B by TMPRSS2/ERG Fusion Isoforms through Toll-Like Receptor-4, Cancer Res 2011 71, 1325-1333.
37. Attard G, Clark J, Ambroisine L, Fisher G, Kovacs G, Flohr P, Berney D, Foster C S, Fletcher A, Gerald W L, Moller H, Reuter V, De Bono J S, Scardino P, Cuzick J, and Cooper C S. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer, Oncogene 2008 27, 253-263.
38. Zhang J, Patel L, and Pienta K J. CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis, Cytokine Growth Factor Rev 2010 21, 41-48.
39. Loberg R D, Ying C, Craig M, Yan L, Snyder L A, and Pienta K J. CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration, Neoplasia 2007 9, 556-562.
40. Tsaur I, Rutz J, Makarevic J, Juengel E, Gust K M, Borgmann H, Schilling D, Nelson K, Haferkamp A, Bartsch G, and Blaheta R A. CCL2 promotes integrin-mediated adhesion of prostate cancer cells in vitro, World J Urol 2014 [Epub ahead of print].
41. Sun T, Mary L G, Oh W K, Freedman M L, Pomerantz M, Pienta K J, and Kantoff P W. Inherited variants in the chemokine CCL2 gene and prostate cancer aggressiveness in a Caucasian cohort, Clin Cancer Res 2011 17, 1546-1552.
42. Lu Y, Chen Q, Corey E, Xie W, Fan J, Mizokami A, and Zhang J. Activation of MCP-1/CCR2 axis promotes prostate cancer growth in bone, Clin Exp Metastasis 2009 26, 161-169.
43. Zhang J, Lu Y, and Pienta K J. Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth, J Natl Cancer Inst 2010 102, 522-528.
44. Li X, Loberg R, Liao J, Ying C, Snyder L A, Pienta K J, and McCauley L K. A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone, Cancer Res 2009 69, 1685-1692.
45. Loberg R D, Ying C, Craig M, Day L L, Sargent E, Neeley C, Wojno K, Snyder L A, Yan L, and Pienta K J. Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo, Cancer Res 2007 67, 9417-9424.
46. Perkins N D. Post-translational modifications regulating the activity and function of the nuclear factor kappa B pathway, Oncogene 2006 25, 6717-6730.
47. Lawrence T, Bebien M, Liu G Y, Nizet V, and Karin M. IKKalpha limits macrophage NF-kappaB activation and contributes to the resolution of inflammation, Nature 2005 434, 1138-1143.
48. Buss H, Dorrie A, Schmitz M L, Hoffmann E, Resch K, and Kracht M. Constitutive and interleukin-1-inducible phosphorylation of p65 NF-{kappa}B at serine 536 is mediated by multiple protein kinases including I{kappa}B kinase (IKK)-{alpha}, IKK{beta}, IKK{epsilon}, TRAF family member-associated (TANK)-binding kinase 1 (TBK1), and an unknown kinase and couples p65 to TATA-binding protein-associated factor II31-mediated interleukin-8 transcription, J Biol Chem 2004 279, 55633-55643.
49. Adli M, and Baldwin A S. IKK-i/IKKepsilon controls constitutive, cancer cell-associated NF-kappaB activity via regulation of Ser-536 p65/RelA phosphorylation, J Biol Chem 2006 281, 26976-26984.
50. Squire J A. TMPRSS2-ERG and PTEN loss in prostate cancer, Nat Genet 2009 41, 509-510.
51. Qu X, Randhawa G, Friedman C, Kurland B F, Glaskova L, Coleman I, Mostaghel E, Higano C S, Porter C, Vessella R, Nelson P S, and Fang M. A three-marker FISH panel detects more genetic aberrations of AR, PTEN and TMPRSS2/ERG in castration-resistant or metastatic prostate cancers than in primary prostate tumors, PLoS One 2013 8, e74671.
52. Li Y, Kong D, Wang Z, Ahmad A, Bao B, Padhye S, and Sarkar F H. Inactivation of AR/TMPRSS2-ERG/Wnt signaling networks attenuates the aggressive behavior of prostate cancer cells, Cancer Prev Res (Phila) 2011 4, 1495-1506.
53. Rizzi F, Naponelli V, Silva A, Modernelli A, Ramazzina I, Bonacini M, Tardito S, Gatti R, Uggeri J, and Bettuzzi S. Polyphenon E(R), a standardized green tea extract, induces endoplasmic reticulum stress, leading to death of immortalized PNT1a cells by anoikis and tumorigenic PC3 by necroptosis, Carcinogenesis 2014 35, 828-839.
54. Degeorges A, Hoffschir F, Cussenot O, Gauville C, Le Duc A, Dutrillaux B, and Calvo F. Recurrent cytogenetic alterations of prostate carcinoma and amplification of c-myc or epidermal growth factor receptor in subclones of immortalized PNT1 human prostate epithelial cell line, Int J Cancer 1995 62, 724-731.
55. Cai C, Wang H, He H H, Chen S, He L, Ma F, Mucci L, Wang Q, Fiore C, Sowalsky A G, Loda M, Liu X S, Brown M, Balk S P, and Yuan X. ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer, J Clin Invest 2013 123, 1109-1122.
56. Shao L, Zhou Z, Cai Y, Castro P, Dakhov O, Shi P, Bai Y, Ji H, Shen W, and Wang J. Celastrol suppresses tumor cell growth through targeting an AR-ERG-NF-kappaB pathway in TMPRSS2/ERG fusion gene expressing prostate cancer, PloS one 8, e58391.
57. Creighton C J, Casa A, Lazard Z, Huang S, Tsimelzon A, Hilsenbeck S G, Osborne C K, and Lee A V. Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis, J Clin Oncol 2008 26, 4078-4085.
58. Cai Y, Wang J, Li R, Ayala G, Ittmann M, and Liu M. GGAP2/PIKE-a directly activates both the Akt and nuclear factor-kappaB pathways and promotes prostate cancer progression, Cancer Res 2009 69, 819-827.
59. Wang J, Stockton D W, and Ittmann M. The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression, Clin Cancer Res 2004 10, 6169-6178.
60. Polnaszek N, Kwabi-Addo B, Wang J, and Ittmann M. FGF17 is an autocrine prostatic epithelial growth factor and is upregulated in benign prostatic hyperplasia, Prostate 2004 60, 18-24.
61. Xin L, Lawson D A, and Witte O N. The Sca-1 cell surface marker enriches for a prostate-regenerating cell subpopulation that can initiate prostate tumorigenesis, Proc Natl Acad Sci USA 2005 102, 6942-6947.
62. Xin L, Teitell M A, Lawson D A, Kwon A, Mellinghoff I K, and Witte O N. Progression of prostate cancer by synergy of AKT with genotropic and nongenotropic actions of the androgen receptor, Proc Natl Acad Sci USA 2006 103, 7789-7794.